These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 36399351)

  • 21. FDA's Unimproved Enforcement of Postmarketing Requirements and Commitments: Implications for Providers and Patients.
    Dauner DG; Dauner KN; Peterson ALH
    Res Social Adm Pharm; 2020 Jun; 16(6):844-847. PubMed ID: 31812502
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Food and Drug Administration's Role in Dermatologic Drug Development.
    Lewis FS; Marcus KA
    Dermatol Clin; 2022 Jul; 40(3):249-263. PubMed ID: 35750409
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Examining the FDA's oversight of direct-to-consumer advertising.
    Gahart MT; Duhamel LM; Dievler A; Price R
    Health Aff (Millwood); 2003; Suppl Web Exclusives():W3-120-3. PubMed ID: 14527243
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FDA Approval and Regulation of Pharmaceuticals, 1983-2018.
    Darrow JJ; Avorn J; Kesselheim AS
    JAMA; 2020 Jan; 323(2):164-176. PubMed ID: 31935033
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Accelerated drug approval: Meeting the ethical yardstick.
    Andreoletti M; Blasimme A
    Bioethics; 2023 Sep; 37(7):647-655. PubMed ID: 37341679
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Examination of the relationship between oncology drug labeling revision frequency and FDA product categorization.
    Berlin RJ
    Am J Public Health; 2009 Sep; 99(9):1693-8. PubMed ID: 19372515
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
    Rossen BR
    Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Export of pharmaceuticals and medical devices under the federal Food, Drug & Cosmetic Act: FDA's striking change in interpretation post-Shelhigh.
    Basile EM; Tolomeo D; Gluck E
    Food Drug Law J; 2009; 64(1):149-69. PubMed ID: 19998744
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An Evaluation of US Food and Drug Administration's Program to Register HIV Drugs for Use in Resource-Constrained Settings.
    Chahal HS; Koukounas K; Capella P; Presto R; Murray JS; Shimer M; Riley K; Valdez ML
    JAMA Netw Open; 2019 Nov; 2(11):e1915787. PubMed ID: 31747034
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Review of the Food and Drug Administration's Center for Drug Evaluation and Research Program for New Molecular Entities: Trends and Regulatory Requirements in Mid-Cycle Communications.
    Hoffman RD; Beattie SD; Camp JR; Fuhs JV
    Ther Innov Regul Sci; 2023 Jul; 57(4):689-701. PubMed ID: 37014601
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FDA's Generic Drug Program: Decreasing Time to Approval and Number of Review Cycles.
    Chazin H; Woo J; Han J; Grosser S; Luan J
    Ther Innov Regul Sci; 2020 Jul; 54(4):758-763. PubMed ID: 32557293
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sipuleucel-T (Provenge(®))-Autopsy of an Innovative Paradigm Change in Cancer Treatment: Why a Single-Product Biotech Company Failed to Capitalize on its Breakthrough Invention.
    Jarosławski S; Toumi M
    BioDrugs; 2015 Oct; 29(5):301-7. PubMed ID: 26403092
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative Expedited Regulatory Programs of U.S Food & Drug Administration and Project Orbis Partners.
    Hotaki LT; Shrestha A; Bennett MP; Valdes IL; Lee SH; Wang Y; Spillman D; MacAulay T; Hunt M; Gervais J; Mafi M; Panetta V; Looi YH; Shum M; Atiek E; Meincke R; Rohr UP; Ainbinder D; Boehm-Cagan A; Luxenburg O; Cerqueira MR; Mouawad LS; Thees MFRES; Prasad K; de Claro RA
    Ther Innov Regul Sci; 2023 Jul; 57(4):875-885. PubMed ID: 37072651
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Medicaid Spending on Drugs Marketed Without US Food and Drug Administration Approval in 2020.
    Gunter SJ; Kesselheim AS; Rome BN
    JAMA Intern Med; 2022 Mar; 182(3):342-345. PubMed ID: 35040875
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FDA's Expedited Programs and Their Impact on the Availability of New Therapies.
    Damle N; Shah S; Nagraj P; Tabrizi P; Rodriguez GE; Bhambri R
    Ther Innov Regul Sci; 2017 Jan; 51(1):24-28. PubMed ID: 30235999
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Estimating the Impact of Food and Drug Administration's Unapproved Drug Initiative on Drug Prices and Sales.
    Sharma D; Schumock GT; Saffore CD; Albert Edwards S; Walton SM
    Ther Innov Regul Sci; 2020 Mar; 54(2):424-430. PubMed ID: 32072591
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The US Food and Drug Administration's tentative approval process and the global fight against HIV.
    Chahal HS; Murray JS; Shimer M; Capella P; Presto R; Valdez ML; Lurie PG
    J Int AIDS Soc; 2017 Dec; 20(4):. PubMed ID: 29232052
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Prescription Drug User Fee Act: Much More Than User Fees.
    Mitchell AP; Trivedi NU; Bach PB
    Med Care; 2022 Apr; 60(4):287-293. PubMed ID: 35149663
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characteristics of Preapproval and Postapproval Studies for Drugs Granted Accelerated Approval by the US Food and Drug Administration.
    Naci H; Smalley KR; Kesselheim AS
    JAMA; 2017 Aug; 318(7):626-636. PubMed ID: 28810023
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Accelerated Approval - Taking the FDA's Concerns Seriously.
    Sachs RE; Donohue JM; Dusetzina SB
    N Engl J Med; 2022 Jul; 387(3):199-201. PubMed ID: 35793197
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.